Avalo Therapeutics Inc (AVTX NASDAQ) stock market data APIs
$13.7598
-0.32(-2.3%)
as of May 1, 2026
Try our APIs with
free plan!
Avalo Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Prev. Close
13.7598
Open
13.4363
High
13.9804
Low
12.9774
52 wk Range
3.39-20.72
Market Cap
312 M
Shares Outstanding
22 788 K
Revenue
59 000
EPS
-0.37
Beta
0.944
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Avalo Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avalo Therapeutics Inc data using free add-ons & libraries
Get Avalo Therapeutics Inc Fundamental Data
Avalo Therapeutics Inc Fundamental data includes:
- Net Revenue: 59 000
- EBITDA: -72 581 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-23
- EPS/Forecast: -1.495
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avalo Therapeutics Inc News
New
Wedbush Reaffirms ARGX, NUVB, FENC At Outperform; Lifts PT For Kiniksa; Keeps NVCR At Neutral
(RTTNews) - The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation ...
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
For Immediate Release Chicago, IL – April 6, 2026 – Today, Zacks Equity Research discusses Indivior Pharmaceuticals INDV, Catalyst Pharmaceuticals CPRX, Theravance Biopharma TBPH, Relmada Therape...
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Quick Read Traders and investors return from the long holiday weekend with an eye towards the beginning of the first-quarter earnings season, which starts in earnest next week on April 14th, when the...
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 and 2023 backed by strong quarterly results, surging mergers and acquisition...
Get Avalo Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
